CGON (CG Oncology) Net Margin %: -5,558.82% (As of Mar. 2026)


CGON CG Oncology Inc CGON
12 GF Score
Price $71.85
! 6 Warning Signs
View Full Analysis

What is CG Oncology Net Margin %?

CG Oncology CGON -1.22% 12 Net Margin % is -5,558.82% as of Mar. 2026. GuruFocus rates CGON with a GF Score™ of 12/100. The stock has 6 warning signs investors should review. Among 946 Biotechnology companies, CG Oncology ranks worse than 87.84% on this metric.

Net margin is calculated as Net Income divided by its Revenue. CG Oncology's Net Income for the three months ended in Mar. 2026 was $-60.20 Mil. CG Oncology's Revenue for the three months ended in Mar. 2026 was $1.08 Mil. Therefore, CG Oncology's net margin for the quarter that ended in Mar. 2026 was -5,558.82%.

The historical rank and industry rank for CG Oncology's Net Margin % or its related term are showing as below:

CGON' s Net Margin % Range Over the Past 10 Years
Min: -23826.96   Med: -7729.5   Max: -123.95
Current: -3682.61

CGON's Net Margin % is ranked worse than
87.84% of 946 companies
in the Biotechnology industry
Industry Median: -88.815 vs CGON: -3682.61

CG Oncology  (NAS:CGON) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

CG Oncology Net Margin % Related Terms

CG Oncology Net Margin % Historical Data

* Premium members only.

The historical data trend for CG Oncology's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CG Oncology Net Margin % Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
-123.95 -18,556.54 -23,826.96 -7,729.50 -3,985.02

CG Oncology Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -66,253.85 0.00 -2,629.53 -1,779.03 -5,558.82

CGON vs CRSP, XENE, TGTX: Net Margin % Comparison

For the Biotechnology subindustry, CG Oncology's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CG Oncology Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's Net Margin % distribution charts can be found below:

* The bar in red indicates where CG Oncology's Net Margin % falls into.


CGON
12GF Score
CG Oncology Inc CGON
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CG Oncology Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

CG Oncology's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-160.995/4.04
=-3,985.02 %

CG Oncology's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-60.202/1.083
=-5,558.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -5,558.82% mean?
CG Oncology (CGON) has a Net Margin % of -5,558.82% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on CG Oncology and its competitors. According to the industry distribution chart, CG Oncology ranks #831 out of 946 companies in the Biotechnology industry, placing it in the top 87.8%.
Is CG Oncology's Net Margin % too high?
CG Oncology's current Net Margin % is -5,558.82%. Based on the distribution chart, CG Oncology ranks #831 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CG Oncology has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does CG Oncology's Net Margin % compare to CRSP and XENE?
According to the Biotechnology industry distribution chart, CG Oncology ranks #831 out of 946 companies for Net Margin %. This places CG Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on CG Oncology and its competitors. CG Oncology's current Net Margin % is -5,558.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CG Oncology stock overvalued right now?
CG Oncology (CGON) has a current Net Margin % of -5,558.82%. The current Net Margin % is -5,558.82%. CG Oncology's overall GF Score™ is 12/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For CG Oncology (CGON), the current Net Margin % is -5,558.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CG Oncology Business Description

Address 400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
12GF Score

Get the complete analysis for CGON

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$71.85
Price